Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr2.71 SEK
Change Today +0.01 / 0.37%
Volume 75.9K
As of 7:50 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

medcap ab (MCAP) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/13/14 - kr4.30
52 Week Low
02/20/15 - kr1.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDCAP AB (MCAP)

Related News

No related news articles were found.

medcap ab (MCAP) Related Businessweek News

No Related Businessweek News Found

medcap ab (MCAP) Details

MedCap AB is a private equity firm specializing in investments in middle markets, mature, turnarounds, buyouts, mezzanine, and bridge financings. It prefers to invest in medical, medical technology, biotechnology, life sciences, and research companies. The firm prefers to invest in companies that are based in Europe with a main focus on the Nordic region and that are not listed on the stock exchange. It typically invests between SEK50 million ($6.63 million) and SEK200 million ($26.51 million) in companies with an enterprise value between SEK50 million ($6.63 million) and SEK200 million ($26.51 million). The firm seeks to acquire stakes between 20% and 50% in its portfolio companies. It uses its capital and loans and makes balance sheet investments. MedCap AB was founded in 2001 and is based in Stockholm, Sweden.

Founded in 2001

medcap ab (MCAP) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr1.8M
Compensation as of Fiscal Year 2013.

medcap ab (MCAP) Key Developments

MedCap AB (publ.) Announces Unaudited Earnings Results for the Fourth Quarter and Year Ended January 2015

MedCap AB (publ.) announced unaudited earnings results for the fourth quarter and year ended January 2015. For the quarter, the company reported net sales of SEK 200 million compared to SEK 223 million a year ago. EBIT was SEK 0.6 million compared to SEK 10.4 million a year ago. Profit before tax was SEK 1.7 million compared to SEK 7.3 million a year ago. Profit for the period was SEK 0.5 million compared to SEK 6.5 million a year ago. Operating income decreased, mainly due to weak performance in Abilia. For the year, the company reported net sales of SEK 890 million compared to SEK 651 million a year ago. EBIT was SEK 8.0 million compared to SEK 32.4 million a year ago. Profit before tax was SEK 11.4 million compared to SEK 23.3 million a year ago. Profit for the period was SEK 11.3 million compared to SEK 20.2 million a year ago. Net loan debt was SEK 57 million compared to SEK 154 million a year ago. Cash flow from operating activities was sEK 62 million compared to SEK 29 million a year ago.

MedCap AB (publ.) to Report Nine Months, 2015 Results on Feb 20, 2015

MedCap AB (publ.) announced that they will report nine months, 2015 results on Feb 20, 2015

MedCap AB (publ.), Annual General Meeting, Aug 29, 2014

MedCap AB (publ.), Annual General Meeting, Aug 29, 2014., at 15:00 Central Europe Standard Time. Location: at company headquarters. Agenda: To consider the election of chairman of the meeting; to elect secretary; to preparation and approval of voting list; to consider election of one or two persons to check the minutes; to consider the presentation of the annual report and the auditors' report and consolidated financial statements and auditor's report for the period May 1, 2013 to April 30, 2014; to consider the decisions on adoption of the balance sheet and income statement and the consolidated balance sheet and consolidated income statement for the period May 1, 2013 to April 30, 2014, allocation of the company's profit or loss according to the adopted balance sheet, and discharge the board and chief executive officer; to consider the determination of the remuneration to the board and the auditor; to consider the election of directors, deputy directors and auditors; to issue authorization; to consider the regarding incentive program for executives in subsidiaries; and to consider the closing of the meeting.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MCAP:SS kr2.71 SEK +0.01

MCAP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MCAP.
View Industry Companies

Industry Analysis


Industry Average

Valuation MCAP Industry Range
Price/Earnings 38.5x
Price/Sales 0.4x
Price/Book 1.4x
Price/Cash Flow 12.9x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDCAP AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at